Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $411.4 million.

  • Janux Therapeutics' Net Cash Flow fell 133.55% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 125.32%. This contributed to the annual value of $411.4 million for FY2024, which is 1376.81% up from last year.
  • Latest data reveals that Janux Therapeutics reported Net Cash Flow of $411.4 million as of FY2024, which was up 1,376.81% from -$32.2 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Net Cash Flow registered a high of $411.4 million during FY2024, and its lowest value of -$32.2 million during FY2023.
  • For the 3-year period, Janux Therapeutics' Net Cash Flow averaged around $131.7 million, with its median value being $15.8 million (2022).
  • Per our database at Business Quant, Janux Therapeutics' Net Cash Flow tumbled by 303.36% in 2023 and then skyrocketed by 1,376.81% in 2024.
  • Over the past 5 years, Janux Therapeutics' Net Cash Flow (Yearly) stood at $7.2 million in 2020, then surged by 299.51% to $28.6 million in 2021, then slumped by 44.57% to $15.8 million in 2022, then tumbled by 303.36% to -$32.2 million in 2023, then spiked by 1,376.81% to $411.4 million in 2024.